Search results: (10000)
News Ixekizumab administered for 5 years demonstrated high efficacy and a favorable safety profile in patients with moderate to severe psoriasis
Ixekizumab is a recombinant humanized monoclonal antibody against interleukin 17A, indicated for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. At the 24th World Congress of Dermatology in Milan in June 2019, results were presented from a study evaluating the efficacy and safety of long-term administration of ixekizumab.
News How Does Memantine Currently Stand in Alzheimer's Disease and Other Dementias
A comprehensive meta-analysis from 2019 examined the effect and safety of administering memantine, particularly in patients with moderate to severe Alzheimer's disease. How did memantine fare?
News Incidence of Thromboembolic Disease During Military Operations – Results of a 10-Year Review
In contemporary armed conflicts, limb injuries account for more than half of all injuries. In addition to the characteristically high incidence of infectious complications, injuries associated with military medicine also carry a high risk of thromboembolic disease. This is demonstrated by a study assessing the incidence of thromboembolic disease in American soldiers over 10 years of military operations in the Middle East.
News Effect of Beta-Blockers on Glucose Metabolism and Their Use in Diabetics with Hypoglycemic Episodes
Beta-blockers, through their mechanism of action, can lead to the deepening or direct initiation of both hypoglycemia and hyperglycemia. The study presented below, published last year, evaluated the impact of beta-blocker treatment, their selectivity, and the predisposition of patients to hypoglycemia on the risk of mortality.
News Do Beta-Blockers Increase the Risk of Hypoglycemia in Patients with Diabetes and Atherosclerosis?
Given that a large portion of patients with diabetes have proven cardiovascular disease, several clinical studies or their subsequent analyses address the effects of beta-blockers in these patients. One such analysis was the post-hoc analysis of the TECOS study, which among other things, attempted to evaluate the connection between the use of beta-blockers in type 2 diabetics with proven atherosclerotic cardiovascular disease and the incidence of hypoglycemic episodes.
News Combination of Candesartan with ACE Inhibitors in the Treatment of Hypertension and Heart Failure
Although the combination of ACE inhibitors and sartans is not recommended due to the higher incidence of complications, studies also indicate a positive effect of their concurrent administration. The potential use of dual blockade of the renin-angiotensin-aldosterone system (RAAS) is suggested in resistant hypertension, and results have also been described in the treatment of congestive heart failure. What do the recommendations say?
News Development of Albuminuria During Treatment with ACE Inhibitors and Sartans
Individual molecules from the class of renin-angiotensin system inhibitors display various distinct properties at the molecular level, and their renoprotective potential may differ. A study by Korean authors observed the development of renal parameters in individuals with albuminuria during the first 3 months after the initiation of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs), also known as sartans.
News Targeted DNA Sequencing Helps Find Targeted Therapy for Patients with NSCLC
Gene sequencing has become a key tool in deciding the treatment for patients with non-small cell lung cancer (NSCLC). At a university in Seoul, South Korea, a retrospective analysis of the benefits of targeted genetic testing in real clinical practice was conducted.
News Modern Techniques and MRI Markers in Multiple Sclerosis Imaging or How to Increase Specificity and Sensitivity of Examinations
MRI is a key component in the diagnosis of multiple sclerosis (MS). However, despite significant progress in imaging methods, specificity is still not optimal. The current trend is to refine and clearly define MRI criteria for diagnosing multiple sclerosis and distinguishing it from MS-mimicking white matter lesions.
News Hypnotics in the Therapy of Insomnia (Not Only) in the Elderly
Problems with insomnia make up a significant part of the subjective complaints, especially of older patients in our clinics. Up to 1/3 of the population may suffer from chronic insomnia symptoms, and the number of people with this problem is continuously increasing. What are our options in its treatment?
News KDIGO: The Choice of Dialysis Modality Must Consider Patient Individuality
The moment of initiating dialysis, as well as the period immediately before and after it, is crucial for good treatment outcomes. But what exactly can be considered a good outcome, and do the perspectives of doctors and patients align on this issue? Leading nephrologists worldwide discussed this at the KDIGO conference, which was specifically focused on controversies in dialysis treatment.
News Overall Survival and Tolerance of Olaparib in the OlympiAD Study – Results of Extended Follow-up
Olaparib provides women with metastatic breast cancer with a germline BRCA mutation, who have not been pre-treated with chemotherapy, not only with extended progression-free survival but also, according to the latest reports, longer overall survival. Its tolerability is good over the long term.
News Safety and efficacy of dabigatran and other NOACs compared with warfarin in patients with atrial fibrillation – results of a large long-term prospective study
Anticoagulant therapy is key in the prevention of strokes in patients with atrial fibrillation. Until the introduction of new oral anticoagulants (NOACs), warfarin was the first-choice drug for these patients, but unlike NOACs, it requires careful dose titration and effect monitoring. The safety and benefits of using various anticoagulants were examined in the study below.
News Perioperative Management in Patients with Atrial Fibrillation Treated with NOACs
The recommended procedures for perioperative management in patients using novel oral anticoagulants (NOACs) stem from the requirement to minimize treatment interruption before and after surgical procedures to reduce the risk of bleeding and thromboembolism. The safety of these regimens in patients with atrial fibrillation was examined in the prospective PAUSE study presented below.
News Impact of Sacubitril/Valsartan Treatment on Left Ventricular Reverse Remodeling
A meta-analysis evaluated the effect of sacubitril/valsartan on echocardiographic parameters (not only) in patients with HFrEF. The authors focused on both the presence and significance of changes, as well as the speed of their onset after the initiation of treatment.